Drug regimens identified and optimized by output-driven platform markedly reduce tuberculosis treatment time
Current antibiotic therapies for tuberculosis are lengthy and onerous. Here, the authors use an output-driven approach to optimize drug doses for two experimental drug regimens in a mouse model of tuberculosis, leading to improved regimens that reduce treatment time by 75%.
Guardado en:
Autores principales: | Bai-Yu Lee, Daniel L. Clemens, Aleidy Silva, Barbara Jane Dillon, Saša Masleša-Galić, Susana Nava, Xianting Ding, Chih-Ming Ho, Marcus A. Horwitz |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/589689ebb4e6419f8418ee3376f93d87 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia
por: Qingmei Jia, et al.
Publicado: (2018) -
Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters
por: Qingmei Jia, et al.
Publicado: (2021) -
Specific marking of hESCs-derived hematopoietic lineage by WAS-promoter driven lentiviral vectors.
por: Pilar Muñoz, et al.
Publicado: (2012) -
Isonicotinylation is a histone mark induced by the anti-tuberculosis first-line drug isoniazid
por: Yuhan Jiang, et al.
Publicado: (2021) -
Increased complement C1q level marks active disease in human tuberculosis.
por: Yi Cai, et al.
Publicado: (2014)